Related Experiment Video
Updated: Aug 31, 2025

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
LncRNA DSCAM-AS1: A Pivotal Therapeutic Target in Cancer
1Medical College, China Three Gorges University, Yichang 443002, China.
Background:
LncRNAs are an emerging category of non-coding RNAs. LncRNAs are usually greater than 200 nucleotides in length and do not possess protein editing capabilities. DSCAM-AS1 is a highly valued member of the lncRNAs family. Numerous studies have revealed the involvement of the oncogene DSCAM-AS1 in multiple biological processes, including metastasis, aggressiveness and cell proliferation. This review discusses the molecular mechanisms and clinical significance of DSCAM-AS1 in various tumor types.
Methods:
This paper analyzes and summarizes current research by searching PubMed using "DSCAM-AS1" and "tumor" as keywords.
Results:
DSCAM-AS1 is a valuable tumor-associated lncRNA with significant oncogenic effects. It is abnormally expressed in a variety of cancers, such as non-small cell lung cancer, cervical cancer, osteosarcoma, colorectal cancer, breast cancer, gastric cancer and endometrial cancer. The overexpression of DSCAM-AS1 promotes cancer progression by modulating cancer cell proliferation, invasion, distant metastasis, and resistance.
Conclusion:
DSCAM-AS1 is upregulated and acts as an oncogene in multiple tumors. As more systematic studies are performed, DSCAM-AS1 may prove to be a promising therapeutic target or tumor biomarker.
Related Concept Videos
lncRNA - Long Non-coding RNAs
Targeted Cancer Therapies
There are several types of targeted therapies against...
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
Abnormal Proliferation

